Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Neurocrine Biosciences Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $14.88, while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | NBIX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $81.00 | $185.50 |
52-Week Low | $11.55 | $123.10 |
Market Cap | — | $15.77B |
Enterprise Value | — | $15.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.49, down 3.55% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, with recent payouts ranging from $0.15 to $0.28. News coverage highlights high distribution yields but also significant NAV erosion, with some sources reporting a 67.45% decline over the past year. Support and resistance are tightly clustered around $15-$16, indicating limited near-term price movement.
The outlook is mixed: high income potential from distributions appeals to yield-seeking investors, but structural risks and capital depreciation pose substantial downside. Investors face uncapped losses despite weekly payouts, with fees and tax implications further eroding returns. Careful risk assessment is essential given the fund's volatility and performance history.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
